commonly used drugs are contraceptive pills and four antibiotics: penicillin V (for respiratory infections), pivmecillinam and trimethoprim (for urinary tract infections) and lymecycline (for acne). more women than men use pain relievers (Table I) . Women who are prescribed anti-inflammatory and anti-rheumatic drugs and milder pain relievers also take somewhat larger amounts on average (based on defined daily doses). more women than men are treated with antidepressants and sleeping pills. However, women and men use approximately the same amounts of these medications in terms of defined daily doses. Figure 2 shows the gender disparity in drug use for some of the most common prescription drug groups. Infections are the most common diagnosis in primary care. The drug group prescribed to the largest number of patients is antibiotics. In 2007, one in every four Swedes received at least one course of antibiotics, with respiratory infection as the most common reason for treatment. more women than men -1.3 million to 1 million -were treated with antibiotics, as urinary tract infections are more prevalent among women (Figure 2a ).
Drugs for cardiovascular diseases are among our most commonly prescribed medications (Figure 2b ). Almost 2 million people were treated with these drugs in 2007. They are also used to prevent cardiovascular illnesses by reducing high blood pressure and blood fats, which explains the large number of recipients.
The anti-inflammatory and anti-rheumatic drug group (Figure 2c ) includes medications that are also administered to relieve mild pain. This type of drug is used by a very large number of people -slightly more women than men. The same applies to the group of pain relievers which includes the opiates, acetaminophen and migraine drugs (Figure 2d ).
Psychotropic drugs are also used more by women than men (Figure 2e and 2f ). This applies largely to sleeping pills and tranquilisers, antidepressants and, to a lesser extent, to drugs for treating psychoses and schizophrenia. Gender disparities in drug use correlate with disparities in morbidity. As mentioned in several chapters in this report, significantly more women than men suffer from nervousness, anxiousness and anxiety and depression. Women are also more prone than men to suffer from aches and pains. more surprising is the fact that drugs for treating cardiovascular diseases are administered with equal frequency to both sexes, although more men than women are affected by these diseases. The most common drugs in this group are drugs for treating high blood pressure. These are equally common among men and women, and tend to even out the gender disparities.
Prescription drugs and the elderly
Today, people aged 80 and over use an average of 5.8 prescription drugs per person. Drug use among the elderly has become increasingly extensive. Since the end of the 1980s it has risen by an average of slightly more than two preparations per person (one preparation per decade), an increase of 60 per cent.
This increase is attributable to the introduction of new drugs and treatment methods [9] . Although medical care has benefited in terms of the ability to provide better treatment of diseases and complaints that affect elderly people, it also involves a significant risk of side effects and drug interactions. The elderly as a group are not only the foremost users of multiple drugs but are the most sensitive to them because of their age and ill health. many of them live in special housing for the elderly, where the use of prescription drugs has risen on average from eight separate medications per person in 1995 to ten, according to current figures [3, 10] . Another growing group comprises people with multiple diseases living in their own homes. A series of studies has shown that people in this group use drugs as extensively as elderly people in special housing [11] [12] [13] [14] [15] .
Can the increasing use of prescription drugs contribute to better health among the elderly?
Use of drugs for treating cardiovascular disease has increased markedly among the elderly. These include antithrombotic agents and lipid-modifying drugs medications, beta-receptor blockers, calcium channel blockers and ACE inhibitors (Table II) .
most of these drugs can be of great benefit to elderly people if administered properly. There is convincing evidence to support this. Clear examples are the beta-receptor blockers and ACE inhibitors, both of which have been shown to have positive effects on both morbidity and survival in the case of heart failure [17] . ACE inhibitors and calcium channel blockers have shown corresponding results in the case of high blood pressure [18] . The drug group comprising antithrombotic agents consists mostly (over 80 per cent) of low-dose aspirin (acetylsalicylic acid). A number of studies have found these drugs to be effective in preventing blood clots during heart attacks or following strokes [18] . There is also convincing evidence that lipid-modifying drugs are effective in preventing cardiovascular diseases. On the other hand, studies have shown that there is limited benefit to be derived from administering lipid-modifying lowering drugs to elderly people who are not suffering from cardiovascular disease (so-called primary prevention) [18] . Other drug groups whose use has increased markedly are those used to treat stomach ulcers and acid reflux disease (recurrent complaints of heartburn). This follows the introduction of so-called proton pump inhibitors (losec ® , lanzo ® , Omeprazole, etc.), which have proved effective in healing stomach ulcers, mainly in the duodenum, and in the symptomatic treatment of acid reflux disease [19] . However, the fact that a large percentage of patients (at least half) with stomach complaints of this type have neither stomach ulcers nor apparent reflux [19] suggest that there may be significant over-prescription in this area.
It has also become more common to medicate with calcium. Calcium, in combination with vitamin D, has been shown to reduce the risk of fractures among elderly women living in special housing. The same effect is also likely to be present among those who live in their own homes [20] .
Antidepressant therapy among the elderly has become far more common. Drugs in the SSRI group, which constitute the overwhelming majority of all antidepressants prescribed today, are recommended as a first-line treatment for depression in the elderly [21] . However, there is little documented evidence on the effects of drug treatment for depression among people over 80 [21, 22] . Studies suggest that antidepressants are often prescribed for the elderly without clear, well-founded medical indication [23] .
Can increasing drug use have adverse effects on the health of the elderly?
As many as one in every five hospitalised elderly patients has been hospitalised due to side effects of a medication, according to both Swedish and international studies [9] . Swedish studies also show that side effects of medication cause twice as many hospitalisations today as in the 1970s [24] . One reason for this could be that more and more elderly people are living longer and living with several chronic illnesses. Extensive drug use is nevertheless a significant risk factor as it increases the probability of side effects, drug interactions and inappropriate drug use [25, 26] .
Certain drugs may be inappropriate for elderly people owing to their heightened sensitivity to side effects. The number of elderly people still being treated with these drugs can serve as an indication of the quality of drug prescription for the elderly [27] . A study in jönköping county (Table III) showed that poor quality in drug use was widespread among the elderly in special housing. Because of their advanced age, the elderly and in many cases their dementia and/or multiple morbidity, should be regarded as a risk group in terms of side effects and other problems resulting from medication [3] .
Anti-cholinergic drugs block the effects of the signal substance acetylcholine and include incontinence drugs, the tranquiliser Atarax ® and the older types of antidepressants. Extensive use of these medications by the elderly are an indication of lack of quality in drug treatment. These medications can cause confusion in the elderly and thus should be avoided as a rule. long-acting benzodiazepines (tranquilisers) can heighten the risk of confusion and accidents resulting from falls. Treatment involving simultaneous administration of several types of psychotropic drugs increases the risk of side effects and drug interactions, and can be a sign of deficiencies in the treatment of psychiatric conditions. According to the medicines Information Portal (FASS.se), drug combinations that can cause class D interactions may "lead to serious clinical consequences in the form of side effects or no effects, or may otherwise be difficult to control with individualised dosages. Combining them should, therefore, be avoided."
Elderly people with multi-morbidity are a growing group requiring multiple medications. Because of their ill health and impaired organ function, these people are particularly sensitive to drugs and in especially great need of high-quality drug treatment. However, several studies in recent years have shown that many of them make extensive use of drugsbetween 9 and 12 preparations per person -often prescribed without sufficient regard for quality [11] [12] [13] [14] [15] .
In 2005 the Swedish National Board of Health and Welfare carried out a register-based study of drug use among elderly people in Sweden with multiple morbidity [5] . The subjects were administered an average of nine drugs per person compared with five in the rest of the elderly population. Quality deficiencies were significantly more common among the multiply ill than among the rest (Table IV) . In particular, it [3] .
was more common for the multiply ill to be taking three or more psychotropic drugs and drug combinations that could produce serious class D interactions.
Drug treatment based on need -social and economic factors
Drug treatment should primarily be based on need, not on other factors such as the patient's income level, education, country of birth or sex. The less well educated use more drugs than the highly educated [28, 29] , a reflection of the greater prevalence of illness among the former [30] . However, there are examples which suggest that drug treatment is not always equitable. For instance, lipid-modifying drugs [31] and oestrogen [29, 32] are used to a greater extent by groups that are socioeconomically better off. Another example is drugs used to treat dementia. Their use is more prevalent among the highly educated than among the less well educated [33] , although the incidence of dementia is greater among the latter [34] . Figure 3 shows how socioeconomic and demographic factors can influence prescription drug use among the population. Even where different population groups have a similar burden of illness, their inclination to seek medical care may vary. This leads to a situation where some groups do not seek care and are therefore not prescribed the necessary drugs (Figure 3, item B) . For example, less well educated people and non-skilled workers make less use of medical care than other groups (in relation to their underlying needs) [35, 36] .
When a person seeks medical care, disparities appear to arise in the way medications are prescribed (Figure 3 , item C). Expectations and knowledge, factors which depend on the patient's level of education, seem to have some impact on the physician's decision to prescribe a drug. The fact that a patient requests a particular drug is also significant [37] .
Studies from the US, Canada and Ireland show that less well-off social groups are less likely to be given newer and more costly drugs [38] [39] [40] . Instead, they are more often prescribed hazardous drugs and harmful drug combinations [41] . To a certain extent this also applies to Sweden. The Swedish National Board of Health and Welfare's analyses of drug use one to two years after hospitalisation conducted in 2005 showed that highly educated people in 2005 used more modern and more expensive types of medication in cases of COPD, heart failure and stroke [42] . People who had been treated for heart attacks also frequently received too few of the [5] . recommended drugs after being discharged from hospital. This applied particularly to people born outside the EU compared to those born in Sweden (Table V) [43] . lower use of recommended drugs also appeared to obtain among those born outside the EU after being treated for heart failure, stroke and COPD [42] . moreover, studies of the elderly in Sweden (aged 75 and older) show that the use of many drugs simultaneously (five or more and ten or more) is somewhat more prevalent among the less well educated than the more highly educated. The former are also more likely to receive inappropriate drug treatment as defined in the quality indicators established by the Swedish National Board of Health and Welfare (cf . Table III ) [44] , and less likely to use the new drugs available on the market [45] . These analyses are based on information from the Swedish Prescribed Drug Register, established on july 1, 2005. The register only contains data on prescribed and purchased drugs; it does not cover drugs that have been prescribed but not purchased. Thus the studies cannot establish whether lower drug use is the result of under-prescribing (Figure 3 , item C) or because the patient has not purchased his or her medications (Figure 3, item D) .
Prescribed, purchased, used
In Sweden we know a good deal about the amount of prescribed drugs purchased at pharmacies. On the other hand, we know less about how much is being prescribed but never purchased (Figure 3 , item C), or about how much is being purchased but never used (Figure 3 , item E). Studies show that patients do not always follow their prescribed drug treatment, particularly in cases of chronic illnesses [46] . The patient's attitude is important; a sceptical attitude, fear of side effects and a general aversion to drugs may mean that the patient will adhere to a drug regime less closely [47, 48] . Patients who do not follow their treatment plan represent a considerable cost to society [49] .
Since the prescription drug system was reformed in 1997, patients have paid a higher percentage of the cost of drugs than previously [50] . Under the current highcost protection scheme, patients do not pay for prescribed drugs if their combined medication expenses over a 12-month period exceed SEk 2,200. Despite this protection, however, patients may refrain from taking out their prescriptions for financial reasons.
In 2005, 3 per cent of the adult population -3.5 per cent of women and 2.5 per cent of men -reported having refrained from purchasing prescribed medications (Table VI) . Of these, nearly 40 per cent of women and just over 30 per cent of men gave lack of money as the main reason. Out of the total population, 1.4 per cent of women and 0.8 per cent of men refrained from purchasing prescription drugsmainly for financial reasons. These figures cannot be compared with those compiled for previous years, when the proportion was higher than 3 per cent, as the questions asked of the interviewees were not fully comparable over time [50] .
Certain groups in the population refrained from purchasing prescription drugs more than others (Table VI) . Women did so more than men, younger people more than older people. Insufficient means was the main reason given. The disparity was also observed in comparisons between people born outside Sweden and native-born citizens. The groups containing the largest percentage of those who refrain from purchasing drugs are: single people with children, the unemployed, early retirees, people receiving sickness and social security benefits, and those with high prescription drug expenses.
For people in these groups, insufficient means is crucial to their decision to do without prescription drugs. Single people with children -usually women as most children are registered with their mothers when the parents live separately -make up one of the groups that most often refrain from purchasing medications. They do so almost three times as often as the population as a whole. The link with disposable income is clear, and the percentage of those who do without drugs, citing inadequate means as the main reason, increases with declining income (Table VI) .
The link between household income and the propensity to refrain from purchasing prescription drugs is confirmed by other Swedish research. This shows a clear link between the level of unfavourable socioeconomic conditions (in this case an index based on whether the individual is receiving social security benefit, is unemployed, is going through a financial crisis or lacks a disposable income) and the decision to refrain from purchasing prescribed drugs -even after taking into account chronic illness, single-person households, a lifestyle full of risks and low confidence in medical care [51] .
Prescription drug costs
The cost of prescription drugs increased by about 10 per cent annually in the period 1986-2002. The rate of increase has since slowed owing to changes in the rules on pharmaceutical benefits, particularly the introduction of generic substitution of medicines (Figure 4 ). medications used by the largest number of people do not necessarily account for the bulk of drug costs. While antibiotics are used by many people, the treatment period is generally short and the total amount of medication used is relatively small, which means costs are also relatively low. Costs rise in the case of medications used over a long period for more chronic conditions. Examples include drugs to prevent cardiovascular disease and for treating asthma, diabetes and depression. Over-the-counter (OTC) drugs are medicines that may be sold directly to a consumer without a prescription from a healthcare professional, as compared to prescription drugs.
Total drug costs are higher for women than for men. This is largely because there are more women than men in the oldest age groups, where drug consumption is greatest. Gender disparities in drug use also lead to differences in costs per person ( Figure 5 ). Costs per person are higher for men, with the exception of age groups in which many women use contraceptive pills or oestrogen preparations. men also incur higher costs than women when broken down by individual user: SEk 4,135 versus SEk 3,683. This is partly because expensive drugs used to treat haemophilia are used mainly by men, whereas contraceptives used by women are cheap. If contraceptive pills and drugs used for haemophilia are removed from the comparison, the cost disparity per patient falls from 452 to 319 kronor.
Within certain but not all drug groups there is also a tendency to prescribe more expensive drugs for men [8] . However, the gender disparity in drug costs cannot be used directly as a basis for judging quality of treatment. An assessment of the differences in men's and women's drug treatment would require a close study of each separate area of treatment. This falls outside the scope of this chapter but is discussed in an earlier report by the Swedish National Board of Health and Welfare [8] .
The group that accounted for the highest costs, 3.7 billion kronor in 2007, included drugs used to treat cardiovascular disease (ATC group C+B01AC). The average annual cost per patient (in this case the person who purchased the drug during the year) was SEk 1,715 for women and SEk 2,062 for men. The cost of drugs used to treat asthma and other respiratory diseases (ATC group R03) was SEk 1.6 billion, at an average annual cost per patient of SEk 2,199 for men and SEk 2,417 for women.
Cancer treatment is also expensive. The total cost of prescription drugs for cancer was SEk 1.1 billion. There is a significant gender disparity with respect to prescribed drugs for treating cancer: SEk 13,903 for men and SEk 5,679 for women. The reason for this is that treatment for prostate cancer is extremely expensive. If drugs for treating prostate cancer (which are also used to treat endometriosis) are removed from the comparison, the cost per patient becomes SEk 4,685 for men and SEk 5,222 for women. most cancer treatment involves specialist hospital care, where the cost of cancer drugs in 2007 was SEk 1.4 billion.
Among the most expensive drugs are a number of extremely costly medications used by small groups of patients. These include drugs for treating haemophilia (average annual cost per patient SEk 1.4 million for men), multiple sclerosis (SEk 98,955 per patient for women) and rheumatic diseases (SEk 89,076 per patient for men, SEk 81,891 for women).
Do we get the new drugs we want?
New drugs are often more expensive than older medications used in the same treatment area. However, by providing new and better treatment possibilities, they can not only relieve suffering but also lower society's medical care costs by reducing the need for other medical care. The past twenty years have seen the emergence of a great many new drugs designed to prevent serious diseases. Statins, which lower high cholesterol, are a well-known example. A number of pharmacotechnologically advanced drugs have also been introduced. Within their respective treatment areas, they have led to new treatment modalities for a smaller number of patients. These drugs are often very expensive; they include certain new cancer drugs, the so-called biological drugs for treating rheumatoid arthritis and drugs used to treat HIV. New medications for the treatment of other major public health problems such as depression and obesity have also been introduced. A drug group that has not seen much development in recent years is antibiotics. However, there is an urgent need for new drugs to treat infections as more and more bacteria become resistant to the antibiotics in use today [52] . The need for new drugs to treat infections has also been emphasised in a WHO report [53] .
The development of new drugs is driven primarily by economic factors. It is thus not surprising that most new medications are developed in treatment areas with a large number of patients, where medication is continuous, perhaps lifelong, or where the medical benefits of new forms of treatment are so great that the drug can be sold at very high prices.
In the case of antibiotics, where the treatment period is of short duration, the potential for high earnings is not as great. Development of new drugs in this drug group is therefore not as intensive. Various proposals have been put forward in a bid to encourage pharmaceutical companies to intensify development of antibiotics and other drugs. This could involve limiting documentation requirements when new, extremely urgent drugs are to be approved, or changing patent regulations so that the patent period only comes into effect once the drug has reached a certain sales volume [54] .
